Academic Psychiatry

, Volume 29, Issue 2, pp 215–221 | Cite as

Psychiatric Training Program Engagement With the Pharmaceutical Industry: An Educational Issue, Not Strictly an Ethical One




To analyze the educational and ethical issues involved in interactions between departments of psychiatry and the pharmaceutical industry.


The author analyzes the history of attitudes toward pharmaceutical companies, various conflicting ethical principles that apply, and areas of confluence and conflict of interest between psychiatric education and the drug industry. These attitudes are applied to a variety of specific types of interactions with representatives of the pharmaceutical industry.


A number of forms of interaction are found to be on balance, ethical, and productive, while others are found to be problematic.


Careful analysis of both ethical and educational dimensions can produce meaningful and constructive involvement with the pharmaceutical industry, without inevitably corrupting psychiatric educators.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Avorn J, Chen M, Hartley R: Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982; 73: 4–8PubMedCrossRefGoogle Scholar
  2. 2.
    Chew LD, O’Young TS, Hazlet TK, et al: A physician survey of the effect of drug sample availability on physicians’ behavior. J Gen Intern Med 2000; 15: 478–483PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Chren MM, Landefeld CS: Physicians’ behavior and their interactions with drug companies: A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994; 271: 684–689PubMedCrossRefGoogle Scholar
  4. 4.
    Orlowski JP, Waleska L: The effects of pharmaceutical firm enticements on physician prescribing patterns. there’s no such thing as a free lunch. Chest 1992; 102: 270–273PubMedCrossRefGoogle Scholar
  5. 5.
    Sandberg WS, Carlos R, Sandberg EH, et al: The effects of educational gifts from pharmaceutical firms on medical students’ recall of company names or products. Acad Med 1997; 72: 916–918PubMedCrossRefGoogle Scholar
  6. 6.
    Spingarn RW, Berlin, JA, Strom BL: When pharmaceutical manufacturers’ employees present grand rounds, what do residents remember? Acad Med, 1996;71: 86–88PubMedCrossRefGoogle Scholar
  7. 7.
    Wysong P. Time with drug reps affects prescribing: study. The Medical Post 8 Sept 1988Google Scholar
  8. 8.
    Hodges B: Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. CMAJ 1995; 153: 553–559PubMedCentralPubMedGoogle Scholar
  9. 9.
    American College of Physicians. Physician-industry relations: part 1: Individual physicians. Ann Intern Med 2002;136: 396–402CrossRefGoogle Scholar
  10. 10.
    American Medical Association, Council of Ethical and Judicial Affairs. Gifts to physicians from industry. JAMA 1991;265: 501CrossRefGoogle Scholar
  11. 11.
    American Medical Association Council on Ethical and Judicial Affairs: Code of Medical Ethics, Clarification of Gifts to Physicians from Industry. 30 Aug 2001Google Scholar
  12. 12.
    Education Council Residency Training Programme in Internal Medicine. Dept of Medicine. McMaster University, Hamilton, Ont. Development of residency program guidelines for interaction with the pharmaceutical industry. Can Med Assoc J: 1993; 149: 405–408Google Scholar
  13. 13.
    Guidance Documents.
  14. 14.
    Pharmaceutical Research and Manufacturers of America. PhRMA code on interactions with healthcare professionals. Available at: Accessed on 8/12/03
  15. 15.
    Whal DS: American Psychiatric Association Ethics Committee. Ethics Primer of the American Psychiatric Association. American Psychiatric Association, 2001Google Scholar
  16. 16.
    Interactions with Pharmaceutical Industry Representatives. Internal Memo of UMass Medical School Office of Psychiatric Education and Training. 6/6/02Google Scholar
  17. 17.
    Policy on Vendor Gifts. Entertainment and Sponsored Meetings and Training. UMass Memorial Health Care Policy Memo. 2/11/03Google Scholar
  18. 18.
    Angell M: Is academic medicine for sale? N Engl J Med 2000; 342: 1516–1518PubMedCrossRefGoogle Scholar
  19. 19.
    Bodenheimer T: Uneasy alliance: clinical investigators and the pharmaceutical industry. N Engl J Med 2000; 342: 1539–1544PubMedCrossRefGoogle Scholar
  20. 20.
    Korn D: Conflicts of interest in biomedical research. JAMA 2000; 284: 2234–2237PubMedCrossRefGoogle Scholar
  21. 21.
    Langreth R: Drug marketing drives many clinical trials. Wall Street Journal 16 Nov 1998Google Scholar
  22. 22.
    Rennie D: Fair conduct and fair reporting of clinical trials. JAMA 1999; 282: 1766–1768PubMedCrossRefGoogle Scholar
  23. 23.
    Montgomery J, Byerly M: Pharmaceutical industry support and outcome of clinical trials presented at University of Texas Southwestern Medical Center Department of Psychiatry Grand Rounds. May 2003Google Scholar
  24. 24.
    Jibson MD: An Ethical Framework for Clinician/Industry Interactions presented at the American Association of Directors of Psychiatry Residency Training Annual Meeting. March, 2003Google Scholar
  25. 25.
    Wazana A: Physicians and pharmaceutical industry: is a gift every just a gift? JAMA 2000; 283: 373–380PubMedCrossRefGoogle Scholar
  26. 26.
    Hopper JA, Speece MW, Musial JL: Effects of an educational intervention on residents’ knowledge and attitudes toward interactions with pharmaceutical representatives. J Gen Intern Med 1997; 12: 639–642PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    McCormick BB, Tomlinson G, Brill-Edwards P, et al: Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on post-training attitudes and behavior. JAMA 2001; 286: 1994–1999PubMedCrossRefGoogle Scholar
  28. 28.
    Rosack J: Residents want education on interacting with drug industry. psychiatric news. Dec 7 2001; 36: 18Google Scholar
  29. 29.
    Shaughnessy AF, Slawson DC, Bennett JH: Teaching information mastery: evaluating information provided by pharmaceutical representatives. Fam Med 1995; 27: 581–585PubMedGoogle Scholar

Copyright information

© Academic Psychiatry 2005

Authors and Affiliations

  1. 1.Dept. of PsychiatryUniversity of Texas Southwestern Medical Center at DallasDallasUSA

Personalised recommendations